Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
24.95
-0.40 (-1.58%)
May 30, 2025, 4:00 PM - Market closed
AAPG Employees
Ascentage Pharma Group International had 567 employees as of December 31, 2024. The number of employees decreased by 16 or -2.74% compared to the previous year.
Employees
567
Change (1Y)
-16
Growth (1Y)
-2.74%
Revenue / Employee
$236,953
Profits / Employee
-$97,964
Market Cap
2.19B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
AAPG News
- 8 days ago - Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 - GlobeNewsWire
- 4 weeks ago - Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin - GlobeNewsWire
- 2 months ago - Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan - Benzinga
- 2 months ago - Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 - GlobeNewsWire
- 3 months ago - Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) - GlobeNewsWire
- 4 months ago - Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares - GlobeNewsWire